Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving our commitment to the advancement of treatments in this field, we are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Food allergies are serious medical conditions that occur when the body has a specific immune response to certain foods. In people with food allergies, the immune system mistakenly responds to a certain food as if it were harmful. The body’s immune response can be potentially life-threatening, such as anaphylaxis, which is a sudden and severe allergic reaction that may cause death.

Investigating a Potential New Class of Immunotherapy through Our Proprietary Technology Platform, Viaskin

As a potential new class of treatment, Viaskin is designed to activate the immune system through the skin, which may offer a self-administered and non-invasive treatment option to patients.

DBV Aims to Unlock the Powerful Immune Properties of the Skin

Our investigational, proprietary treatment is based on EPIT. This potential new class of immunotherapy is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin platform.

For patients facing life-threatening food allergies, this investigational immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin.

We are developing the Viaskin technology platform to help improve the lives of patients suffering from peanut and other food allergies. Programs in development include late stage clinical trials of Viaskin Peanut and Viaskin Milk, as well as pre-clinical studies of Viaskin Egg.

DBV’s robust development program includes ongoing clinical trials of Viaskin Peanut and Viaskin Milk and pre-clinical development of Viaskin Egg.

Viaskin’s potential to unlock the immune properties of skin makes it a promising therapeutic approach beyond food allergies. DBV is investigating other areas of significant unmet medical need, including Eosinophilic Esophagitis (EoE), vaccines, inflammatory conditions and autoimmune diseases.